LAVA Therapeutics N.V.
$1.74-3.87%($-0.07)
TickerSpark Score
74/100
65
Valuation
20
Profitability
100
Growth
84
Health
100
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LVTX research report →
52-Week Range77% of range
Low $0.85
Current $1.74
High $2.00
Companywww.lavatherapeutics.com
LAVA Therapeutics N. V. , a clinical-stage immuno-oncology company, focuses on developing cancer treatments.
- CEO
- Stephen Allen Hurly
- IPO
- 2021
- Employees
- 34
- HQ
- Utrecht, NL
Price Chart
+12.26% · this period
Valuation
- Market Cap
- $45.77M
- P/E
- -2.01
- P/S
- 9.17
- P/B
- 3.69
- EV/EBITDA
- 0.18
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -391.98%
- Op Margin
- -591.70%
- Net Margin
- -466.45%
- ROE
- -108.07%
- ROIC
- -61.92%
Growth & Income
- Revenue
- $11.98M · 77.01%
- Net Income
- $-25,114,000 · 40.02%
- EPS
- $-0.94 · 40.13%
- Op Income
- $-29,693,000
- FCF YoY
- 52.29%
Performance & Tape
- 52W High
- $2.00
- 52W Low
- $0.85
- 50D MA
- $1.59
- 200D MA
- $1.39
- Beta
- 0.50
- Avg Volume
- 346.58K
Get TickerSpark's AI analysis on LVTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 25 | Powell Fred M | sell | 124,700 |
| Nov 13, 25 | Powell Fred M | sell | 65,000 |
| Nov 13, 25 | Wadlinger Mary E. | sell | 33,390 |
| Nov 13, 25 | Oliger Christy J. | sell | 33,390 |
| Nov 13, 25 | Noble James | sell | 33,390 |
| Nov 13, 25 | Kiener Peter A | sell | 33,390 |
| Nov 13, 25 | Backstrom Jay T. | sell | 33,390 |
| Nov 13, 25 | WILSON KAREN J | sell | 33,390 |
| Nov 13, 25 | WILSON KAREN J | sell | 10,000 |
| Nov 13, 25 | Dhingra Kapil | sell | 33,390 |
Our LVTX Coverage
We haven't published any research on LVTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LVTX Report →Similar Companies
CALC+4.47%
CalciMedica, Inc.
$0.65
LTRN+2.59%
Lantern Pharma Inc.
$3.17
ATNM+1.74%
Actinium Pharmaceuticals, Inc.
$1.17
TVRD+3.77%
Tvardi Therapeutics, Inc.
$3.85
XLO+3.18%
Xilio Therapeutics, Inc.
$8.44
PDSB+3.00%
PDS Biotechnology Corporation
$1.03
CELU+2.37%
Celularity Inc.
$0.83
RVPH-3.46%
Reviva Pharmaceuticals Holdings, Inc.
$0.39